Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
FIVE PRIME THERAPEUTICS, INC. (FPRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/03/2020 |
8-K
| Quarterly results |
| 08/06/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results |
| 02/27/2020 |
8-K
| Quarterly results |
| 11/06/2019 |
8-K
| Quarterly results|
Docs:
|
"Five Prime Therapeutics Reports Third Quarter 2019 Results SOUTH SAN FRANCISCO, Calif.——November 6, 2019— Five Prime Therapeutics , Inc. , a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced its results for the third quarter and provided an update on the company's recent activities. “We have advanced all of our wholly-owned programs according to our plan for 2019,” said Willilam Ringo, Chairman and interim Chief Executive Officer of Five Prime Therapeutics. “As we approach 2020, we have repositioned Five Prime with a focus on prioritizing our pipeline based on upcoming data readouts, while also extending our cash runway, in order to maximize the long-term potential of the company.” Third Quarter 201..." |
|
| 08/07/2019 |
8-K
| Quarterly results |
| 05/08/2019 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 4, 2019 Five Prime Therapeutics, Inc. Delaware 001-36070 26-0038620 111 Oyster Point Boulevard South San Francisco, California 94080 Registrant's telephone number, including area code: 365-5600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐...",
"Five Prime Therapeutics Reports First Quarter 2019 Results SOUTH SAN FRANCISCO, Calif.—--May 8, 2019— Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced its results for the first quarter and provided an update on the company's recent activities. The company also provided an update on the Phase 3 FIGHT trial testing bemarituzumab in combination with mFOLFOX6 in patients with gastric or gastroesophageal junction cancer that overexpresses FGFR2b. “We and our partners have made steady progress advancing all five clinical programs in our pipeline, and we are swiftly responding to new information from the Phase 3 FIGHT trial,” said Aron Knickerbocker, Chief Executive Officer..." |
|
| 02/26/2019 |
8-K
| Quarterly results |
| 11/06/2018 |
8-K
| Quarterly results |
| 08/08/2018 |
8-K
| Quarterly results |
| 05/08/2018 |
8-K
| Quarterly results |
| 02/27/2018 |
8-K
| Quarterly results |
| 11/06/2017 |
8-K
| Quarterly results|
Docs:
|
"FORM 8-K",
"Five Prime Announces Third Quarter 2017 Results and Provides Business Update SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2017 — Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the quarter ending September 30, 2017. “This is an exciting time at Five Prime, as many of our programs are reaching important inflection points,” said Lewis T. “Rusty” Williams, M.D., Ph.D., president and chief executive officer of Five Prime. “Importantly, later this week at the SITC annual meeting, we and BMS plan to report our first clinical data from the Phase 1a/1b immuno-oncology trial studying cabiralizumab with OPDIVO ® . The oral late-br..." |
|
| 08/08/2017 |
8-K
| Quarterly results|
Docs:
|
"FORM 8-K",
"Five Prime Announces Second Quarter 2017 Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., August 8, 2017 — Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the quarter ending June 30, 2017. “We continued to make significant progress on our clinical and pre-clinical programs during the quarter,” said Lewis T. “Rusty” Williams, M.D., Ph.D., president and chief executive officer of Five Prime. “We are advancing our large Phase 1a/1b immuno-oncology trial studying cabiralizumab with OPDIVO ® in multiple tumor settings. We completed enrollment in some of the cohorts and are on track to complete enrollme..." |
|
| 05/04/2017 |
8-K
| Form 8-K - Current report |
| 02/23/2017 |
8-K
| Form 8-K - Current report |
| 11/03/2016 |
8-K
| Form 8-K - Current report |
| 05/05/2016 |
8-K
| Form 8-K - Current report |
| 03/10/2016 |
8-K
| Form 8-K - Current report |
| 11/04/2015 |
8-K
| Quarterly results |
| 08/06/2015 |
8-K
| Quarterly results |
| 05/13/2015 |
8-K
| Quarterly results|
Docs:
|
"Five Prime Therapeutics Announces First Quarter 2015 Financial Results SOUTH SAN FRANCISCO, Calif., May 13, 2015, — Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the first quarter ending March 31, 2015. “We made important progress in all of our programs during the first quarter of 2015 and remain on track to deliver on a number of key milestones over the next 12 months,” said Lewis T. “Rusty” Williams, M.D., Ph.D., Founder and Chief Executive Officer of Five Prime. “For FPA008, our CSF1 receptor antibody, we anticipate initiating two additional clinical trials in mid-2015: the first is the nivolu..." |
|
| 03/17/2015 |
8-K
| Quarterly results|
Docs:
|
"Five Prime Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results SOUTH SAN FRANCISCO, Calif., March 17, 2015, — Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2014. “2014 was a remarkable year for Five Prime,” said Lewis T. “Rusty” Williams, M.D., Ph.D., Founder and Chief Executive Officer of Five Prime. “We began the year with two candidates in the clinic and our pipeline has now grown to three clinical-stage therapeutics covering 11 indications. We have substantially broadened our presence in immuno-oncology through a new ..." |
|
| 11/10/2014 |
8-K
| Quarterly results|
Docs:
|
"Five Prime Therapeutics Announces Third Quarter 2014 Financial Results SOUTH SAN FRANCISCO, Calif., November 10, 2014, — Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ending September 30, 2014. “Since the second quarter, we have made tremendous progress in support of our pipeline and strategy,” said Lewis T. “Rusty” Williams, M.D., Ph.D., president and chief executive officer of Five Prime. “We recently received IND clearance for our Phase 1 trial of FPA144, which means we now have three therapeutic candidates in the clinic. As a monoclonal antibody, FPA144 represents an immunot..." |
|
| 08/05/2014 |
8-K
| Quarterly results |
| 05/08/2014 |
8-K
| Quarterly results|
Docs:
|
"Five Prime Therapeutics Announces First Quarter 2014 Financial Results SOUTH SAN FRANCISCO, Calif., May 8, 2014, — Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the first quarter that ended March 31, 2014. “We began the year with positive momentum from our immuno-oncology collaboration with Bristol-Myers Squibb and with the successful completion of our follow-on public offering,” said Lewis T. “Rusty” Williams, M.D., Ph.D., president and chief executive officer of Five Prime. “Our strong balance sheet puts us in an excellent position to continue the development of our lead pipeline candidates and..." |
|
| 03/25/2014 |
8-K
| Quarterly results|
Docs:
|
"Five Prime Therapeutics Announces Fourth Quarter and Fiscal 2013 Financial Results SOUTH SAN FRANCISCO, Calif., Mar. 25, 2014 — Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended Dec. 31, 2013. “2013 was a transformational year for Five Prime with many important milestones. In addition to our initial public offering and the announcement of key partnerships, we made considerable progress with our lead clinical candidates. Two arms of the Phase 1b study of FP-1039, an FGF ligand trap, are now enrolling with our partner GSK and the healthy volunteer dose escalation porti..." |
|
| 11/12/2013 |
8-K
| Form 8-K - Current report |
|
|